Bone Marrow Mononuclear Cells Transfer for Patients after ST-Elevated Myocardial Infarction: A Meta-Analysis of Randomized Control Trials.
10.3349/ymj.2018.59.5.611
- Author:
Jingyi ZHANG
1
;
Li LIN
;
Wenxia ZONG
Author Information
1. Department of Cardiovascular Medicine, The Third People's Hospital of Hubei Province, Hubei, China. wenxiazong123@163.com
- Publication Type:Meta-Analysis ; Randomized Controlled Trial ; Original Article
- Keywords:
ST elevation myocardial infarction;
stroke volume;
bone marrow transplantation;
left ventricular dysfunction
- MeSH:
Bone Marrow Transplantation;
Bone Marrow*;
Cell- and Tissue-Based Therapy;
Follow-Up Studies;
Humans;
Myocardial Infarction*;
Percutaneous Coronary Intervention;
Stroke Volume;
Ventricular Dysfunction, Left
- From:Yonsei Medical Journal
2018;59(5):611-623
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Results on the clinical utility of cell therapy for ST-elevated myocardial infarction (STEMI) are controversial. This study sought to analyze the efficacy of treatment with intracoronary bone marrow mononuclear cells (BMMC) on left ventricular (LV) function and remodeling and LV diastolic and systolic function in patients with STEMI. MATERIALS AND METHODS: Literature search of PubMed and EMBASE databases between 2004 and 2017 was performed for randomized controlled trials in STEMI patients who underwent successful percutaneous coronary intervention and received intracoronary BMMC therapy. The defined end points were left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV). Also, sensitivity analysis and several subgroup analyses based on follow-up duration, timing of injection, doses of cells, and imaging modalities were conducted to strengthen the statistic power of the study. RESULTS: A total of 22 trials with 1360 patients were available for the current meta-analysis. The pooled statistics showed a significant improvement in LVEF {2.58 [95% confidence interval (CI), 1.32, 3.84]; p < 0.001}, LVEDV [−3.73, (95% CI, −6.94, −0.52), p=0.02], and LVESV [−4.67, (95% CI, −7.07, −2.28), p < 0.001] in the BMMC group, compared with the control group. However, in sensitivity analysis, a significant reduction in LVEDV disappeared, while the outcomes of LVEF and LVESV remained unchanged. The same results were presented in the subgroup analysis adjusting for imaging modalities and timing of cells injection. CONCLUSION: BMMC transplantation in patients with STEMI was found to lead to improvement in LVEF, LVEDV, and LVESV parameters, indicating that cell therapy has a potential beneficial effect on LV remodeling and function.
